When I first began looking into the hidden chemistry of mRNA technology, I expected complexity, but I did not expect to find evidence that could shake the foundations of the entire platform (timecodes below).
That evidence has now been brought forward by Christie Grace. In her review of the science, she highlights a critical blind spot: lipid nanoparticles (LNPs) are not chemically inert. They break down into reactive fragments that can permanently bind to RNA, DNA, or proteins. These permanent chemical scars are called adducts. And if they occur in the body as they do in the lab, they represent a problem that no amount of rebranding or reassurance can erase.
The mechanism is clear: as LNPs degrade, they generate aldehydes and peroxides. These molecules are highly reactive, forming covalent adducts with nucleic acids and proteins. In Moderna’s own study, RNA bases were shown to form adducts — particularly adenine — with rates increasing at warmer temperatures. At −20 °C, the damage slowed. At body temperature, 37 °C, the chemistry accelerated.
Adducted RNA does not behave normally. It may fail to translate at all, or it may produce truncated fragments that misfold. If proteins or DNA are caught in this chemistry, the consequences could include misfolding, mutagenesis, or autoimmune activation against newly distorted shapes. These aren’t fringe ideas — they are well-established outcomes of adduct biology in toxicology.
Here is where the story takes a darker turn. The International Council for Harmonisation (ICH) M7 guidelines already recognize that genotoxic impurities are unacceptable in pharmaceuticals, even at trace levels. Entire drug classes have been withdrawn because of them. By those standards, LNP-derived aldehydes should have been investigated with urgency. But that never happened.
Why? Because mRNA vaccines were categorized as “vaccines,” not “gene therapies.” That simple regulatory choice meant they escaped the genotoxicity testing rules that apply to other drugs. No long-term adduct studies. No systematic monitoring. The entire class of products moved forward without clearing the very safety standards designed to catch these risks.
Christie Grace has now put this on the table. If her interpretation is correct, and if independent studies confirm in vivo adduct formation, then this is not a tweakable side effect — it is a platform-ending flaw. The very chemistry of RNA–LNP delivery may be incompatible with safe, long-term human use.
I don’t make such statements lightly. But I believe the public deserves to understand the full picture. For years, the narrative has focused on the success story: speed, innovation, global rollout. The harder questions — about long-term stability, about impurities, about adducts — were left unasked. Now, as the evidence mounts, it becomes harder to ignore.
The truth is stark: if lipid nanoparticles are forming adducts inside the body, the mRNA platform may not just be risky — it may be fundamentally untenable.
This is the chemistry Christie Grace has exposed. And it is chemistry that could take down the entire platform.
Censored post on LinkedIn here:
Timecodes
00:00 – Opening: Why This Science Matters
02:10 – Introducing Christie Grace and Her Background
05:00 – Speaking Out: Risks and Motivation
08:15 – Could This Science Take Down the Platform?
12:00 – What Are Adducts? The Superglue Effect
16:40 – Genotoxic Impurities and the ICH M7 Standard
21:30 – How Vaccines Escaped Genotoxicity Testing
27:00 – Lipid Nanoparticles vs. DNA Contamination
33:20 – RNA Bases Damaged by Lipid Breakdown
39:00 – Permanent Scars: Protein and DNA Adducts
46:15 – Lessons from Past Drug Withdrawals
53:40 – Moderna’s Own Study: Lipids Binding RNA
59:20 – Heat Effect: More Adducts at 37 °C
1:04:00 – Why Repair Systems Can Be Overwhelmed
1:10:15 – Industry Silence and Regulatory Gaps
1:15:00 – Final Reflections: A Platform-Ending Flaw?
Vejon COVID-19 Review is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.
